![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Argonaut Technologies to Sell Stock and Certain Assets to Biotage AB
Argonaut Technologies to Sell Stock and Certain Assets to Biotage AB
February 22, 2005
Argonaut Technologies has entered into a definitive agreement under which Argonaut Technologies will sell stock and certain assets of its consumables and flash chromatography business to Biotage AB of Uppsala, Sweden. The transaction is valued at approximately $20 million in cash, and once consummated will fulfill the first phase of the company's planned effort to maximize shareholder value through strategic transactions. The closing of the transaction is subject to approval by Argonaut's stockholders, and other customary closing conditions.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19134620&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct